雜志介紹

Clinica Chimica Acta雜志介紹

《Clinica Chimica Acta》是一本以English為主的未開放獲取國際優秀期刊，中文名稱Acta 化學診所，本刊主要出版、報道醫學-MEDICAL LABORATORY TECHNOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為3.2，最新CiteScore 指數為10.1。

本刊近期中國學者發表的論文主要有：

• A rapid multiplex assay of human malaria parasites by digital PCR

  Author: Dong, Liu; Li, Weijia; Xu, Qianqian; Gu, Jianfei; Kang, Zhihua; Chen, Jian; Xu, Xiao; Zhang, Xinju; Zhang, Xiuming; Jiang, Haoqin; Guan, Ming

• The value of lipid metabolites 9,10-DOA and 11,12-EET in prenatal diagnosis of fetal heart defects

  Author: Fang, Yiwei; Zhang, Zheng; Zhao, Yun; Sun, Guoqiang; Peng, Meilin; Liu, Chunyan; Yi, Guilin; Zhao, Kai; Yang, Hui

• Biomarkers for chemotherapy and drug resistance in the mismatch repair pathway

  Author: Dong, Liu; Jiang, Haoqin; Kang, Zhihua; Guan, Ming

• Long noncoding RNA HAND2-AS1: A crucial regulator of malignancy

  Author: Huang, Ziyue; Wang, Zhensheng; Xia, Haoming; Ge, Ziqiang; Yu, Liang; Li, Jiehan; Bao, Haolin; Liang, Zixin; Cui, Yunfu; Xu, Yi

英文介紹

Clinica Chimica Acta雜志英文介紹

The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.

The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal's scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.